Predictive biomarkers of immunotherapy response are critical for clinical practice. In this study, baseline plasma sCD27 was ...
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the ...
Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...
NEW YORK - A Ludwig Cancer Research study has identified a key barrier to the efficacy of a promising combination of ...
(NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an ...
Researchers developed an innovative nano-immune agonist that significantly improves immunotherapy outcomes for melanoma - a ...
9d
The therapy, a fully human monoclonal antibody, targets a newly identified immune checkpoint protein that could enhance ...
The therapy, a fully human monoclonal antibody, targets a newly identified immune checkpoint protein that could enhance ...
While PD-1/PD-L1 blockade has demonstrated remarkable clinical successes, recent studies suggest that its novel target has a ...
SPP1+ Macrophages Identified as Key Drivers and Therapeutic Targets In Colorectal Cancer Progression
Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related deaths worldwide.
MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy
Macbecin II was identified as a compound that upregulates MHC-I expression, enhancing immune-mediated cancer cell killing. In ...
Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer: Where Are We Going, What Are We Doing, and Why? The following represents disclosure information provided by the author of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback